Cognitive Function Among Heart Transplant Recipients Before and After Intravenous Iron Supplement for Iron Deficiency: Results From a Randomized, Placebo-Controlled, Double-Blind Treatment Trial.

What Was Tested

The paper reports a study of Copper (Supplement), published as a randomized controlled trial.

Cognitive dysfunction after successful heart transplantation (HTx) is not uncommon.

Trial Registration: ClinicalTrials.gov identifier: NCT03662789.

Who Took Part

The study group was 94 participants.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

In the "Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients" (IronIC) trial, the researchers assessed cognitive function at baseline and at 6-month follow-up with the following tests of the Cambridge Neuropsychological Test Automated Battery: Reaction Time, Paired Associates Learning, and Spatial Working Memory.

Of 94 participants with cognitive data at baseline and follow-up, 49 were randomized to the single intravenous iron supplement, while 45 received placebo.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Copper (Supplement) group a baseline to be compared against.

What Was Measured

PubMed files the paper under topics including Anemia, Iron-Deficiency, Cognition, Cognitive Dysfunction, Dietary Supplements, Heart Transplantation, Iron and Neuropsychological Tests.

The authors tagged it with the keywords cognition disorder, iron deficiencies, mental processes and randomized controlled trial [publication type].

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in 94 participants.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Clinical transplantation), a journal based in Denmark.

More context: the Copper (Supplement) compound page, all human trials.